Arpesh Mehta

Bodi Zhang

Dr. Bodi Zhang currently serves Chief Strategy Officer of Thorne HealthTech. Previously, Dr. Bodi Zhang has served as Chief Science Officer for Onegevity Health, LLC from January 2018 until its merger with our company in March 2021. Prior to his current role, Dr. Zhang served as Vice President, Corporate and Medical Strategy from January 2015 to 2018, and as General Manager, Strategic Alliance from January 2013 to 2015. Prior to joining our company, Dr. Zhang worked at Deallus Group, a global healthcare consultancy. Prior to the Deallus Group, Dr. Zhang was a Research Assistant Professor of Pharmacology at Tufts University, Boston. As a scientist, Bodi’s research focused on autoimmune diseases and published top-tier research publications, including in Proceedings of the National Academy of Sciences, The Journal of Allergy and Clinical Immunology and Nature Reviews. Dr. Zhang holds a Ph.D in Pharmacology and Biochemistry from Tufts University, Boston, an M.P.H in healthcare management from Harvard University, Boston and a M.D. from Peking University, China.

Courtney Stanton

Dondeena Bradley

Laura Kunces

Dr. Laura Kunces currently serves as VP of Medical Strategy of Thorne HealthTech. Previously, Laura served as SVP of Strategic Marketing for Onegevity Health, LLC from March 2019 until its merger with Thorne in March 2021. Before Onegevity, Laura was the Director of Medical Affairs and Clinical Research at Thorne, The Director of Nutrition Research at Arla Foods, and the Director of Research at EXOS, and an Assistant Professor at Central Connecticut State University. Laura earned her PhD from the nationally top-ranked Kinesiology Department at the University of Connecticut with a focus in nutrition. Laura holds two Master’s Degrees, one in Exercise Physiology from the University of Connecticut and one in Clinical Nutrition from the University of Memphis. Her undergraduate Bachelor of Science is in Nutritional Sciences from the University of Connecticut, where she was also a four-year D1 collegiate swimmer. She has been a registered dietitian for 15 years. Her expertise is in sports nutrition, clinical nutrition, personalized wellness, and metabolism research and communications.

Holly Jackson

Tom Weldon

Tom has 35 years of senior management experience, primarily in the medical device industry, both early stage and public companies.  He is a well-known entrepreneur and venture capitalist and holds nearly two dozen patents.  He has founded over a dozen companies, which in total have created over $2 billion in shareholder value.  He was also the co-founder and Chairman of a top quartile venture fund, Accuitive Medical Ventures, which raised a total of $230 million across two funds, and is now fully invested. Tom is the Founder, Chairman and CEO of Ponce de Leon Health (PDLH), a company with a mission to extend the length and quality of human life.  PDLH is the world leading longevity company, and the only company to have demonstrated both safety and efficacy in humans with its product. The company has launched Rejuvant, a once-a-day pill shown to reduce biologic age, as measured by DNA methylation testing.

A recently published paper in Aging, demonstrated that subjects who took a DNAm test, then were on Rejuvant for an average of 7 months, then re-tested, had an average decrease in their biologic age of 8 years.

Tom co-founded The Innovation Factory in 1999 and served as its Chairman.  Through his role at The Innovation Factory, he has co-founded AcuFocus, AqueSys, LipoSonix, Neuronetics, and Sebacia.  He was a director on the RespiCardia board, prior to its sale to Zoll Medical, and was formerly the Chairman of LipoSonix, prior to its sale to Medicis. 

He was previously the co-founder, Chairman, and CEO of Novoste Corporation, which utilized intracoronary radiation therapy for the treatment of restenosis.  Tom was Chairman and CEO of Novoste from its inception in 1992 and led the company through its initial public offering in 1996.  Prior to that, Tom was the co-founder and CEO of Novoste Puerto Rico until its sale in 1992.  Before founding Novoste, Tom held positions with Arthur Young & Company and Key Pharmaceuticals in various business and project management roles.

Tom received his M.B.A in Operations and Systems Management from Indiana University in 1981 and his B.S. Industrial Engineer from Purdue University in 1977.  Tom has been recognized by Purdue University in 2007 by receiving the Distinguished Engineer Alumni Award, Outstanding Industrial Engineer Award in 2006, and the Burton Morgan Entrepreneurship Award in 2005.  He also received the Junior Achievement ImpACT Award in 2003.

Tom’s major philanthropic focus is the Weldon School of Biomedical Engineering at Purdue University, established in 2004, and the Weldon Foundation, Inc.  He also serves on the advisory board for the Weldon School of Biomedical Engineering, the Advisory Board for the Buck Institute for Research on Aging and the National University of Singapore School of Medicine International Council.

Chris Meaney